Recipharm AB, a contract development and manufacturing organization (CDMO), has acquired the Lisbon, Portugal-based based CDMO Lusomedicameta Sociedade Técnica Farmacêutica S.A.

Lusomedicamenta is primarily a CDMO specialized in the development and manufacture of solid, liquid and semisolid dose forms as well as sterile ophthalmic products. It operates from two sites located close to Lisbon and has invested heavily in the production of effervescent tablets with anew dedicated facility for this purpose. The company is also focused on new products carrying the management of the whole process from product development to the registration dossier. Lusomedicamenta employs around 340 people and produces over 150 formulations in more than 600 SKUs, exporting to some 45 countries worldwide.

The initial equity consideration of EUR 111 million ($138 million) has been paid, EUR 67.1 million ($83.2 million) in cash and EUR 43.9 million ($54.4 million) in RECI B equity in kind representing 3,500,000 shares. A further EUR 1.3 million ($1.61 million) may be paid in cash subject to the final outcome of 2014. Transaction costs are estimated to be less than EUR 1.5 ($1.86) million.

Source: Recipharm